1. Home
  2. AZTR vs SPHL Comparison

AZTR vs SPHL Comparison

Compare AZTR & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

BUY

Current Price

$0.12

Market Cap

7.9M

Sector

Health Care

ML Signal

BUY

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

BUY

Current Price

$2.25

Market Cap

7.1M

ML Signal

BUY

Company Overview

Basic Information
Metric
AZTR
SPHL
Founded
2014
2002
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.1M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
AZTR
SPHL
Price
$0.12
$2.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 628.4K
203.8K
Earning Date
11-11-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 5.06
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.10
$0.36
52 Week High
$1.09
$25.11

Technical Indicators

Market Signals
Indicator
AZTR
SPHL
Relative Strength Index (RSI) 31.49 43.15
Support Level $0.10 N/A
Resistance Level $0.15 $3.17
Average True Range (ATR) 0.01 0.27
MACD -0.00 -0.02
Stochastic Oscillator 5.06 4.70

Price Performance

Historical Comparison
AZTR
SPHL

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: